Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US69329Y1047
Ticker PDLI
Company PDL BIOPHARMA
Currency $
Price
Aware Investor Index (AII) 33.8660
Recommendation STRONG BUY
P/E 2.62
ROE 21.93 %
Capitalization 485,959,270 $
Dividend Yield 0.00 %
P/S 1.52
AII Position 60
P/E Position 5
ROE Position 135
Capitalization Position 713
Dividend Yield Position 596
Sales 320,060,000 $
10-Year Average Earnings 185,490,200 $
Shares Outstanding 156,257,000
Equity 845,890,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
PDL BIOPHARMA Investor Relations Web Site http://investor.pdl.com







Sales:

YEAR MONTH AMOUNT
2017 12 320,060,000.00 $
2016 12 244,301,000.00 $
2015 12 590,448,000.00 $
2014 12 581,225,000.00 $
2013 12 442,921,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 110,748,000.00 $
2016 12 63,606,000.00 $
2015 12 332,795,000.00 $
2014 12 322,244,000.00 $
2013 12 264,530,000.00 $
2012 12 211,669,000.00 $
2011 12 199,389,000.00 $
2010 12 91,874,000.00 $
2009 12 189,660,000.00 $
2008 12 68,387,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 845,890,000.00 $
2016 12 755,423,000.00 $
2015 12 695,952,000.00 $
2014 12 460,437,000.00 $
2013 12 113,489,000.00 $
2012 12 -68,122,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 156,257,000
2016 12 164,192,000
2015 12 163,554,000
2014 12 173,110,000
2013 12 159,343,000
2012 12 146,403,000

 












Bloomberg News for PDL BIOPHARMA:



Google News for PDL BIOPHARMA:

Nasdaq Click - 7 hours ago
Have a look at Analyst Actions: PDL BioPharma, Inc. (PDLI)
PDL BioPharma, Inc. (PDLI)'s stock fee update: PDL BioPharma, Inc. (PDLI) stock rate ended its day with loss -1.58% and finalized at the rate of ...
Fairfield Current - 9 hours ago
PDL BioPharma (PDLI) Stock Rating Upgraded by Zacks Investment ...
PDL BioPharma (NASDAQ:PDLI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued ...
The RNS Daily
PDL BioPharma, Inc. (PDLI) Could Be Remarkably Fruitful
Some analysts have a lowest price target on PDL BioPharma, Inc. (NASDAQ:PDLI) of $3, which would mean a -5.06% gain in value.
Preston Business Review
Investor Checklist Stocks: Navios Maritime Partners LP (NMM) and ...
PDL BioPharma, Inc. (PDLI) shares have moved -2.51% in the week and 6.51% in the month. Year to date is 7.24%, 21.96% over the last ...
Reagents Global Market
Instantly Trying To Create Change: Live Nation Entertainment, Inc ...
PDL BioPharma, Inc. (NASDAQ:PDLI) subtracted -2.19% to its trading price by the close of the most recent session, dropping from its previous ...
The RNS Daily - 1 day ago
Blunt response to the situation: Infinera Corporation (INFN), PDL ...
PDL BioPharma, Inc.(NASDAQ: PDLI) common stock has recently come under the judgmental eyes of top market analysts. For this stock's ...
Talk Traders (press release) (blog)
Buy, Sell? What To Make Of It All? PDL BioPharma, Inc. (PDLI), Yelp ...
PDL BioPharma, Inc. (NASDAQ:PDLI) sank -0.64% this week, a trend that has led to both investors and traders taking note of the stock.
BharataPress
Loxo Oncology, Inc. (LOXO) is at $233.26 per share and PDL ...
PDL BioPharma, Inc. (PDLI) stock moved with shift of -2.51% in the past week. During the last month, the stock has changed 6.51% and ...
Wallstreet Investorplace
Pdl Biopharma $PDLI Technical Update
The Pdl Biopharma (NASDAQ: PDLI) update and the technical summary table below can help you manage risk and optimize returns. We have ...
Talk Traders (press release) (blog) - 5 hours ago
Where PDL BioPharma (PDLI) stock is going ahead? Now Reached ...
Volume Evaluation. Active moving action has been spotted in PDL BioPharma (PDLI) on Tuesday as stock is moving on change of 2.08% from ...


Back